Adamax
N-acetyl semax amidate (reported)
Adamax (N-acetyl semax amidate (reported)) is a cognitive & mood research compound. Reported longer-acting Semax-family nootropic — BDNF/neurotrophic and dopaminergic modulation.
Adamax quick facts
| Reported research dosing (Injectable) | 200-800mcg |
| Route | Subq |
| Cycle length | 4-8 Weeks |
| Frequency | 1-2x Daily Am/Mid Day · 5 On 2 Off or Daily |
| Half-life | ~3-4 hrs (intranasal) |
| Forms | Injectable, Nasal |
| Evidence level | Anecdotal; sparse data |
| Other forms available | Nasal — dosed differently |
Semax's stronger cousin by reputation. Data is thin — I treat claims cautiously.
How Adamax works
Reported longer-acting Semax-family nootropic — BDNF/neurotrophic and dopaminergic modulation.
Proposed benefits
Longer-acting Semax-family focus and neurotrophic support (thin data).
Where to get Adamax
Adamax is sold in 2 forms. They are not interchangeable — the dose and the route differ, so pick the one this page describes unless you know why you want another.
Adamax reconstitution calculator
Research reconstitution calculator
Bacteriostatic water is the diluent — sterile water with 0.9% benzyl alcohol, which is what lets a vial be drawn from more than once. It does not come with the vial, and unlike the compound it is bought again every time.
Need bacteriostatic water? Get it at AminoWell USA (my company) → Code CAMERON.
The evidence for Adamax
Graded by what exists behind each claim.
Human clinical evidence
- No human trials: development stopped at preclinical, so the ceiling on any claim here is a rodent model — and these transfer poorly.
📊 Correlative data
- Limited community use, mostly by people already using Semax. Reported experience is described as a stronger, longer version of Semax with more emotional flattening in some users.
- Beyond that the record is self-reported: community dosing logs are real information about tolerability and almost none about efficacy.
🧪 How the mechanism reads
- An adamantane-modified Semax analog — the adamantyl group increases lipophilicity and metabolic stability, the same modification strategy that produced bromantane.
- The modification is expected to increase potency and duration, not change the mechanism: the same ACTH(4-10) fragment biology and BDNF/NGF upregulation. Anyone describing a categorically different effect is describing dose.
Why an empty tier is not a verdict → · What community dosing logs are worth →
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Adamax actually does
The first thing this page has to say is that nobody has published what this molecule is. A search of the entire PubMed corpus for “adamax” returns papers about a machine-learning optimization algorithm. There are zero indexed records describing a peptide by that name — no synthesis paper, no pharmacology, no toxicology, no pharmacokinetics, no case report. Everything below is therefore reasoning from the Semax literature about what a molecule bearing this name would do if it is what it is sold as, and that conditional is doing real work.
It gets worse, because the two circulating descriptions are different molecules. One says N-acetyl Semax amidate — the Semax heptapeptide with its N-terminus acetylated and its C-terminus amidated. The other says an adamantane-modified Semax analog, adamantyl being the cage hydrocarbon that makes bromantane and memantine lipophilic. Those are not two descriptions of one thing. They differ in mass, in charge, in lipophilicity and in predicted behavior, and they cannot both be right.
The arithmetic that settles it, and it needs one mass spectrum. Semax is C37H51N9O10S, average mass 813.9, monoisotopic 813.348 National Center for Biotechnology Information 2026. Acetylating the N-terminus adds C2H2O, +42.01; amidating the C-terminal carboxyl swaps OH for NH2, −0.98. Net +41.03, giving roughly 855.0 average mass. Adding an adamantyl group in place of a hydrogen adds C10H14, about +134.1, giving about 948. Those two candidates sit 93 Da apart, which any mass spectrometer separates trivially. A certificate of analysis reporting a mass would end this question in one line, and no vendor publishes one.
Now the part that is real: what Semax actually is and how it is destroyed. Semax is the ACTH(4-10) fragment Met-Glu-His-Phe with Pro-Gly-Pro appended — and that tail was added for exactly one reason, to obstruct carboxypeptidase attack on the C-terminus. Dolotov 2004 measured the binding and the breakdown in rat forebrain: specific, reversible, time-dependent binding to plasma membranes of the basal nuclei with a Kd of 2.41 ± 1.02 nM and a Bmax of 33.5 ± 7.9 fmol/mg protein, a half-life on those membranes of more than 1 hour, and degradation by dipeptidylaminopeptidases cleaving the peptide sequentially to the pentapeptide HFPGP and then the tripeptide PGP.
That degradation route is the entire mechanistic case for the N-acetyl amidate version, and it is a good one. The measured breakdown is dipeptide clipping from the N-terminus. N-acetylation removes the free alpha-amino group that aminopeptidases and dipeptidyl peptidases require, and C-terminal amidation removes the free carboxyl that carboxypeptidases require. So “N-acetyl Semax amidate” is precisely the pair of modifications a chemist would make to defeat the two published exit routes for this peptide. The design is sound. Whether it was ever executed, and whether the resulting molecule still binds, is what nobody has shown.
And there is a real reason to doubt it is a straight improvement. The C-terminal fragment left behind, Pro-Gly-Pro, is not inert — the glyprolines are a studied family in their own right in the same Russian literature. If part of Semax's effect runs through PGP released by degradation, then blocking degradation removes that contribution while extending the parent's life. A protected analog could be longer-acting and less effective at the same time. Nobody has tested it in either direction.
Cell, rodent, human — and where it stops
There is no cell-to-rodent-to-human chain for Adamax, because there is no Adamax literature. What follows is the Semax chain, stated at each step, so a reader can see exactly how far the inheritance can reasonably be carried.
Step one, membranes in a tube. Rat forebrain basal nuclei plasma membranes, radiolabeled Semax, specific and reversible binding at Kd 2.41 nM, with degradation to HFPGP and PGP by dipeptidylaminopeptidases and a membrane half-life above 1 hour Dolotov 2004. Nanomolar affinity for something in brain membrane is a real finding; note that the paper describes binding, not a named receptor.
Step two, rodent, in vivo, and the numbers are specific. Dolotov 2006 gave rats a single 50 µg/kg intranasal dose and measured the hippocampus: BDNF protein up 1.4-fold, trkB phosphorylation up 1.6-fold, exon III BDNF mRNA up 3-fold, trkB mRNA up 2-fold, with improved conditioned avoidance behavior. Dolotov 2003 had already shown Semax raising BDNF expression across several brain regions in vivo. This is a coherent, quantified neurotrophic signal from a single low-dose intranasal administration, and it is the strongest thing this family has.
Step three, humans: for Semax, a Russian clinical literature exists in stroke and cognitive indications. For Adamax, nothing. No trial, no case series, no published pharmacokinetics, no adverse event report.
The obstacles, and there are three distinct ones. (1) The identity obstacle is unique to this compound and comes first: two incompatible structures are in circulation and no analysis distinguishes them. (2) The binding obstacle. The 2.41 nM affinity was measured for native Semax Dolotov 2004. Acetylating the N-terminus deletes a positive charge and amidation deletes a negative one — for a 7-residue peptide, altering the charge at both termini is not a cosmetic change, and no binding assay has ever been run on the modified molecule. (3) The route obstacle. The rodent result is intranasal at 50 µg/kg Dolotov 2006; this product is sold for subcutaneous injection as well as nasal use, and the two routes do not deliver the same thing to the brain. Intranasal delivery of peptides is argued to exploit olfactory and trigeminal pathways directly into the CNS; a subcutaneous dose must survive plasma and cross the blood-brain barrier. Nothing in the Semax literature validates the subcutaneous route for a central endpoint.
Adamax pharmacokinetics — how much of it actually gets in
No pharmacokinetic study of this compound exists in any species. What follows is bounded inference from the parent peptide, and the bounds are wide.
What degrades the parent, measured. Semax is cleaved by dipeptidylaminopeptidases sequentially from the N-terminus to HFPGP then PGP, with a half-life above 1 hour on rat brain plasma membranes Dolotov 2004. That membrane figure is not a plasma half-life and should not be quoted as one — peptidase activity in whole blood is far higher than on a washed membrane preparation, so the circulating half-life of native Semax is certainly shorter, plausibly minutes.
What the modifications would be expected to do, if they are real. Blocking both termini against exopeptidase attack is the standard way to extend a short peptide's life, and it works — it is the same strategy that gives hexarelin its 77% subcutaneous bioavailability. A plausible expectation is a severalfold extension, not an order of magnitude, because endopeptidases and renal filtration remain untouched. A 855 Da peptide is well below the glomerular filtration cutoff and will be cleared renally whatever you do to its ends.
The oral question has one answer and it is short. No published oral bioavailability figure exists for Semax or for any analog, and none should be expected to be meaningful: a hydrophilic peptide with a computed XLogP of −2.8 National Center for Biotechnology Information 2026 facing gastric acid, pancreatic proteases and the intestinal brush border is a textbook case of an oral route that does not work. Neither a cytochrome nor a hepatic esterase is the relevant clearing enzyme here; peptidases are.
Where the site's own 3–4 hour intranasal figure comes from is not stated anywhere in the literature. The only measured duration in this family is the >1 hour membrane half-life Dolotov 2004, and the only measured in vivo dose is 50 µg/kg intranasally in a rat Dolotov 2006 — which for a 70 kg human scales to roughly 3.5 mg by simple body-weight scaling and to a few hundred micrograms by surface-area scaling. The 200–800 µg doses in use land inside that second range, which is the one piece of good news in this section: the dosing is not obviously wrong, it is just not derived from anything.
What would have to be true, and how you would know it was not
The useful predictions here are the ones that rule things out, because that is what an evidence vacuum most needs.
1. Cortisol (AM) and ACTH should not move, and if they do, something other than the advertised mechanism is happening. Semax is the ACTH(4–10) fragment, and the steroidogenic activity of ACTH lives in the 1–24 sequence at the melanocortin-2 receptor. A 4–10 fragment has no capacity to drive the adrenal cortex. So the mechanistic prediction is explicit: draw morning cortisol and ACTH at baseline and at 4 weeks, and expect both flat. This is the cheapest available test of whether the product is the peptide it claims to be, because most things that would contaminate or substitute for it — and the stress-axis effects people attribute to it — would show up here.
2. Cognitive effect should be measurable acutely, and should not accumulate. The rodent finding is a single-dose effect at 50 µg/kg Dolotov 2006. Run Trail Making A and B, and a MoCA, at baseline, at 60–90 minutes after a single dose, and again at 4 weeks of daily use. The Semax mechanism predicts an acute effect that is present on day 1; the BDNF/trkB story predicts an additional slower component. If nothing is measurable acutely on day 1, the acute pharmacology is not there, and a claimed effect at week 4 has practice effects and expectation to compete with.
3. The prediction that cuts against the product: a longer-acting Semax may be a weaker Semax. If part of the parent's activity is carried by its degradation products — HFPGP and PGP, both released by the measured cleavage route Dolotov 2004 — then a molecule engineered not to degrade generates less of them. The falsifiable version: at matched molar dose, an N-terminally protected analog should produce a smaller acute effect than native Semax with a longer tail. Anybody who has both can run this against a Trail Making B on alternate days, and it is the single most informative comparison available to a self-experimenter here.
4. And the identity test, which is not a blood test. Ask the vendor for a mass. 855 means N-acetyl Semax amidate; 948 means an adamantyl adduct; 814 means it is plain Semax National Center for Biotechnology Information 2026. Three numbers, 93 to 134 Da apart, on an instrument every peptide manufacturer already owns.
What nobody has tested yet
Nobody has published a structure, an assay, or a single measurement of this compound. That is the headline unknown and everything else is downstream of it. The experiment is not a trial; it is one LC-MS run on a vial, and it would resolve a question that thousands of people are currently answering by trusting a product page.
Nobody has measured whether N-terminal acetylation preserves binding. Dolotov 2004 gives the exact assay to use: rat forebrain basal nuclei plasma membranes, radiolabeled ligand, competition against native Semax, Kd 2.41 nM as the benchmark. If the acetylated amidate binds with comparable affinity, the analog concept is validated; if affinity collapses, the extended half-life is irrelevant because the molecule no longer engages the target. This is a one-week experiment in a competent pharmacology lab and it has never been done for any Semax analog sold commercially.
Nobody has compared intranasal with subcutaneous delivery for a central endpoint. Every quantified central effect in this family — the 1.4-fold BDNF rise, the 1.6-fold trkB phosphorylation, the 3-fold exon III mRNA rise — came from intranasal dosing Dolotov 2006. The product is widely used subcutaneously. A rat study giving matched doses by both routes and measuring hippocampal BDNF would answer whether the injection route reproduces the effect at all, and it is a small, cheap, obvious study that nobody has published.
And nobody has tested the metabolite hypothesis. Whether HFPGP and PGP contribute to Semax's activity is answerable by giving each fragment separately at equimolar dose in the same behavioral model Dolotov 2004. Until somebody does, “more stable therefore better” is an assumption rather than a finding.
Adamax — its own safety story, not its class's
There is no safety information about this compound. None at all. No toxicology, no adverse event reports, no human exposure record, no published dose that has ever been given to a person under observation. The class safety block on this page describes cholinergic and dopaminergic nootropics and is not about this molecule.
The specific hazard here is identity, not pharmacology. Two incompatible structures circulate under one name, the peptide's parent has a well-characterized profile and the analog has none, and there is no assay on the vial. A buyer cannot distinguish N-acetyl Semax amidate from adamantane-modified Semax from plain Semax from an inactive powder, and the difference between the first and third of those changes both the duration and, plausibly, the dose that is appropriate. The correct posture toward a compound whose structure is unresolved is to treat the dose as unknown, which means starting at the bottom of any range and changing one variable at a time.
What the parent peptide's profile does and does not license. Semax has decades of Russian clinical use and a reputation for being well tolerated, and it is fair to say the parent has a benign record. That does not transfer automatically. Chemical modification changes distribution, duration and off-target binding, and the entire purpose of the modification claimed here is to make the molecule last longer — which means any effect it has, wanted or not, is also present for longer.
The one mechanism-based caution worth stating. If the compound genuinely raises BDNF and trkB signaling the way its parent does at 50 µg/kg in rats Dolotov 2006, that is a growth-factor pathway, and growth-factor pathways are not obviously neutral when driven daily for months. The rodent work is single-dose. Nothing in this literature speaks to chronic upregulation of a neurotrophin system in a healthy adult brain, and the honest statement is that the chronic-use case has never been examined in any species.
Route matters for the risk too. The dosing card lists both subcutaneous injection and nasal administration. Injection adds sterility and injection-site risk to a compound with no published purity standard, and it is the route with the least supporting evidence for a central effect in this family.
Sources read for this page
- Dolotov OV, Zolotarev IuA, Dorokhova EM. [The binding of Semax, ACTH 4-10 heptapeptide, to plasma membranes of the rat forebrain basal nuclei and its biodegradation].. Bioorg Khim 2004 · PMID 15344653
- Dolotov OV, Karpenko EA, Inozemtseva LS. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.. Brain Res 2006 · PMID 16996037
- Dolotov OV, Seredenina TS, Levitskaya NG. The heptapeptide SEMAX stimulates BDNF expression in different areas of the rat brain in vivo.. Dokl Biol Sci 2003 · PMID 14556513
- National Center for Biotechnology Information. PubChem Compound Summary for CID 9811102, Semax.. PubChem, retrieved 2026
Adamax — safety, predicted from mechanism
Predicted from mechanism, not from a human safety trial. How that reasoning works →
What the mechanism predicts
Derived from the molecule, not a trial.
- This class is broad, but the predicted problems cluster by mechanism rather than by molecule. Cholinergics (racetams, and anything raising acetylcholine) predict headache — the classic one, from choline demand outrunning supply. Dopaminergics and eugeroics predict tolerance, sleep disruption and a flat mood on the days off. Anything glutamatergic or AMPA-facing carries a theoretical excitotoxicity concern at high doses.
- The pattern worth internalizing: anything that borrows performance from tomorrow eventually presents the bill. Sleep is the most common currency it gets paid in.
What has actually been reported
- Headache is the most reported effect across the racetam family and usually responds to added choline.
- Irritability, blunted affect and a rebound low on cessation are commonly reported with the stimulant-adjacent members.
- Most of this class has little or no controlled human safety data at the doses actually used.
How to reduce the risk
Same mechanism as the prediction.
- Take a choline source with any racetam. The headache is the mechanism running out of substrate, and it is largely preventable rather than something to push through.
- Dose in the morning. Almost everything in this class has a longer functional tail than its half-life suggests, and sleep is the first thing you lose.
- Use them for something, not as a habit. The compounds that carry tolerance genuinely reward intermittent use aimed at a task, and genuinely punish daily use aimed at feeling normal.
- One at a time, and long enough to judge it. This is the class where people stack five and cannot tell you which one is doing anything — and the effects are subjective, so attribution is already hard enough.
- If you need it to feel normal, stop. That is the line where a tool has become a dependency, and it is the one worth watching for.
What it does to your bloodwork
A fact about the assay.
- No routine marker tracks these. Sleep is the assay — if it is degrading, the compound is costing more than it is producing, and that shows up before anything else does.
Don't run this if
- A seizure history — several of these lower the threshold at least theoretically, and it is not worth establishing empirically.
- Bipolar disorder, for the dopaminergic members especially.
- Alongside prescribed psychiatric medication without knowing exactly how the mechanisms overlap.
The honest unknown
- Chronic use is essentially uncharacterized. The specific unmeasured thing is what daily cholinergic or dopaminergic pressure does to baseline function over years — not whether a few weeks is tolerable.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this with a pharmacist or doctor.
Food is not a factor — pick a time you will keep
Nothing you eat touches a subcutaneous injection, so there is no meal to plan around. What does matter is a fixed slot: the commonest reason an injectable protocol underperforms is missed doses, not mistimed ones.
With a short half-life, dose it near the effect you want rather than at a fixed hour.
From half-life and route, not a dosing trial.
Adamax — interference & stacking
Predicted from mechanism, not from an interaction study. How mechanism-predicted claims are made →
What Adamax moves on your bloodwork
Expected direction, not a measured one.
- Comprehensive Metabolic Panel (CMP) — ◆ worth watching
Most of this class has no predicted marker movement at all, and saying so is more useful than listing markers that will not move.
What to do: A baseline liver panel is reasonable for anything taken daily and long-term. Beyond that there is nothing specific to chase.
Everything on this page, in an order
This one is free and stays free. What Skool adds is the rest of the shelf — 278 compounds and 371 supplements with the protocol, the stack order and the bloodwork to run beside it.
Join Skool — $10/mo →Bloodwork to run alongside Adamax
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid disease imitates every cognitive complaint there is |
| Vitamin B12 | Deficiency causes fog long before it causes anemia |
| Methylmalonic Acid (MMA) | Catches the deficiency a normal B12 hides |
| Ferritin | Low iron flattens cognition at levels most labs call fine |
| Vitamin D (25-Hydroxy) | Commonly low, cheap to correct, associated with mood |
The Brain Fog & Cognition panel covers these in one order — 12 markers, $233.06 with the discount applied.
Check results you already have → · All 103 markers A–Z
Adamax — frequently asked questions
What is Adamax?
Adamax (N-acetyl semax amidate (reported)) is a cognitive & mood research compound. Reported longer-acting Semax-family nootropic — BDNF/neurotrophic and dopaminergic modulation.
What dosing does the research reference for Adamax?
In the research literature, Adamax is referenced in the 200-800mcg range, 1-2x Daily Am/Mid Day · 5 On 2 Off or Daily. It is supplied as a lyophilized powder and reconstituted with bacteriostatic water; the calculator above converts a research amount into syringe units. For research use only — not a recommendation for human use.
What is the half-life of Adamax?
Adamax has an approximate half-life of ~3-4 hrs (intranasal), which is part of what determines how often it's dosed.
What forms does Adamax come in?
Adamax is available as: Injectable, Nasal.
What's the evidence behind Adamax?
Current evidence level: Anecdotal; sparse data. Adamax is offered for research purposes only and is not an approved medicine.
Adamax inside a finished plan
One arm of 1 Protocol Blueprint, free to read in full.
What Adamax is used for
Adamax appears under 1 goal in the goal router.
Related Cognitive & Mood compounds
Where this goes next
Adamax is the bdnf arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.